CryoCell Operating Income from 2010 to 2026
| CCEL Stock | USD 3.40 0.04 1.16% |
Operating Income | First Reported 1996-02-29 | Previous Quarter 1.5 M | Current Value 1.9 M | Quarterly Volatility 1.9 M |
Check CryoCell International financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CryoCell International's main balance sheet or income statement drivers, such as Depreciation And Amortization of 625.6 K, Selling General Administrative of 11.5 M or Total Revenue of 18.9 M, as well as many indicators such as Price To Sales Ratio of 2.41, Dividend Yield of 0.0245 or Days Sales Outstanding of 79.7. CryoCell financial statements analysis is a perfect complement when working with CryoCell International Valuation or Volatility modules.
CryoCell | Operating Income | Build AI portfolio with CryoCell Stock |
Latest CryoCell International's Operating Income Growth Pattern
Below is the plot of the Operating Income of CryoCell International over the last few years. Operating Income is the amount of profit realized from CryoCell International operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of CryoCell International is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. CryoCell International's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CryoCell International's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
CryoCell Operating Income Regression Statistics
| Arithmetic Mean | 2,350,797 | |
| Geometric Mean | 3,111,317 | |
| Coefficient Of Variation | 185.18 | |
| Mean Deviation | 2,729,685 | |
| Median | 3,480,284 | |
| Standard Deviation | 4,353,133 | |
| Sample Variance | 18.9T | |
| Range | 20M | |
| R-Value | 0.10 | |
| Mean Square Error | 20T | |
| R-Squared | 0.01 | |
| Significance | 0.70 | |
| Slope | 87,485 | |
| Total Sum of Squares | 303.2T |
CryoCell Operating Income History
Other Fundumenentals of CryoCell International
CryoCell International Operating Income component correlations
Click cells to compare fundamentals
About CryoCell International Financial Statements
CryoCell International investors utilize fundamental indicators, such as Operating Income, to predict how CryoCell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | 4 M | 4.2 M | |
| Non Operating Income Net Other | -970.4 K | -921.9 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of CryoCell International Correlation against competitors. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.31) | Dividend Share 0.65 | Earnings Share (0.06) | Revenue Per Share | Quarterly Revenue Growth (0.03) |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.